Targeting the tumor vascular compartment to improve conventional cancer therapy
- PMID: 15380938
- DOI: 10.1016/j.tips.2004.08.008
Targeting the tumor vascular compartment to improve conventional cancer therapy
Abstract
The fact that a single blood vessel can support the life of thousands of tumor cells has been known for a long time. However, therapeutic strategies that aim to impair vascular development in tumors are only slowly emerging in the clinics. Nevertheless, the accumulation of data from many successful preclinical studies of the effects of a variety of drugs that target tumor vasculature provides clues that should help rationalize future treatment modalities for human tumors. Indeed, the 'old' view of an immature and non-functional vascular network within tumors has evolved and, in this article, we will show that the concept of tumor heterogeneity should be extended to the vascular compartment. In addition, we will review recent data documenting that both mature and immature vessels coexist within tumors and, importantly, that their relative density responds to a dynamic process that evolves with time and treatments.
Similar articles
-
Vascular targeting therapy: potential benefit depends on tumor and host related effects.Exp Oncol. 2010 Sep;32(3):143-8. Exp Oncol. 2010. PMID: 21403608 Review.
-
Recent advances in tumor vasculature targeting using liposomal drug delivery systems.Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309. doi: 10.1517/17425240903289928. Expert Opin Drug Deliv. 2009. PMID: 19780711 Review.
-
Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Mol Aspects Med. 2011. PMID: 21540050 Review.
-
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?Clin Lung Cancer. 2005 Nov;7(3):175-9. doi: 10.3816/CLC.2005.n.032. Clin Lung Cancer. 2005. PMID: 16354311 Review.
-
Vascular normalization: a real benefit?Cancer Chemother Pharmacol. 2011 Aug;68(2):275-8. doi: 10.1007/s00280-011-1683-z. Epub 2011 Jun 3. Cancer Chemother Pharmacol. 2011. PMID: 21638121 Review.
Cited by
-
MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis.Front Pharmacol. 2011 May 13;2:111. doi: 10.3389/fphar.2011.00111. eCollection 2011. Front Pharmacol. 2011. PMID: 21687519 Free PMC article.
-
Microbubble and ultrasound radioenhancement of bladder cancer.Br J Cancer. 2012 Jul 24;107(3):469-76. doi: 10.1038/bjc.2012.279. Epub 2012 Jul 12. Br J Cancer. 2012. PMID: 22790798 Free PMC article.
-
Nanovehicular intracellular delivery systems.J Pharm Sci. 2008 Sep;97(9):3518-90. doi: 10.1002/jps.21270. J Pharm Sci. 2008. PMID: 18200527 Free PMC article. Review.
-
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.Cancer Res. 2008 Nov 1;68(21):9033-40. doi: 10.1158/0008-5472.CAN-08-1723. Cancer Res. 2008. PMID: 18974149 Free PMC article.
-
Tackling TAMs for Cancer Immunotherapy: It's Nano Time.Trends Pharmacol Sci. 2020 Oct;41(10):701-714. doi: 10.1016/j.tips.2020.08.003. Trends Pharmacol Sci. 2020. PMID: 32946772 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources